Neuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation by Karen-Sue B. Carlson et al.
fncel-10-00154 June 13, 2016 Time: 12:23 # 1
ORIGINAL RESEARCH
published: 15 June 2016
doi: 10.3389/fncel.2016.00154
Edited by:
Francesco Moccia,
University of Pavia, Italy
Reviewed by:
Nigel Peter Birch,
University of Auckland, New Zealand
Tet Woo Lee,
University of Otago, New Zealand
*Correspondence:
Bradford S. Schwartz
bschwartz@morgridge.org;
bschwartz@medicine.wisc.edu
†Present address:
Karen-Sue B. Carlson,
Department of Internal Medicine,
Medical College of Wisconsin,
Milwaukee, WI, USA;
Lan Nguyen,
Department of Medicine
and Pediatrics, University of Indiana,
Indianapolis, IN USA;
Kat Schwartz,
National Institutes of Health, National
Center for Advancing Translational,
Science, Bethesda, MD, USA
‡These authors have contributed
equally to this work.
Received: 18 November 2015
Accepted: 27 May 2016
Published: 15 June 2016
Citation:
Carlson K-SB, Nguyen L,
Schwartz K, Lawrence DA and
Schwartz BS (2016) Neuroserpin
Differentiates Between Forms
of Tissue Type Plasminogen Activator
via pH Dependent Deacylation.
Front. Cell. Neurosci. 10:154.
doi: 10.3389/fncel.2016.00154
Neuroserpin Differentiates Between
Forms of Tissue Type Plasminogen
Activator via pH Dependent
Deacylation
Karen-Sue B. Carlson1,2†‡, Lan Nguyen3†‡, Kat Schwartz3†, Daniel A. Lawrence4 and
Bradford S. Schwartz1,3*
1 Department of Biomolecular Chemistry, University of Wisconsin, Madison, WI, USA, 2 Medical Scientist Training Program,
University of Wisconsin, Madison, WI, USA, 3 Departments of Biochemistry and Medicine, University of Illinois, Urbana, IL,
USA, 4 Departments of Medicine and Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
Tissue-type plasminogen activator (t-PA), initially characterized for its critical role in
fibrinolysis, also has key functions in both physiologic and pathologic processes in
the CNS. Neuroserpin (NSP) is a t-PA specific serine protease inhibitor (serpin) found
almost exclusively in the CNS that regulates t-PA’s proteolytic activity and protects
against t-PA mediated seizure propagation and blood–brain barrier disruption. This
report demonstrates that NSP inhibition of t-PA varies profoundly as a function of pH
within the biologically relevant pH range for the CNS, and reflects the stability, rather
than the formation of NSP: t-PA acyl-enzyme complexes. Moreover, NSP differentiates
between the zymogen-like single chain form (single chain t-PA, sct-PA) and the mature
protease form (two chain t-PA, tct-PA) of t-PA, demonstrating different pH profiles for
protease inhibition, different pH ranges over which catalytic deacylation occurs, and
different pH dependent profiles of deacylation rates for each form of t-PA. NSP’s pH
dependent inhibition of t-PA is not accounted for by differential acylation, and is specific
for the NSP-t-PA serpin-protease pair. These results demonstrate a novel mechanism
for the differential regulation of the two forms of t-PA in the CNS, and suggest a potential
specific regulatory role for CNS pH in controlling t-PA proteolytic activity.
Keywords: neuroserpin, tissue plasminogen activator, serpin, serine protease, decacylation
INTRODUCTION
Tissue t-PA was initially described as an intravascular protease capable of initiating fibrinolysis
by activation of plasminogen to plasmin (Collen, 1980). However, t-PA is also an important
extravascular protease in the central nervous system (CNS). T-PA participates in axonal
remodeling, neuronal plasticity, long-term potentiation (Seeds et al., 1995), propagation of
excitotoxin-induced seizures (Qian et al., 1993; Tsirka et al., 1995; Endo et al., 1999; Wu et al.,
2000; Yepes et al., 2002; Pawlak et al., 2005; Fredriksson et al., 2015), progression of cerebral
infarct volume during ischemic stroke (Wang et al., 1998; Kano et al., 2000; Yepes et al.,
2000), and regulation of blood brain barrier permeability in a number of pathologic conditions
Abbreviations: NSP, neuroserpin; PAI-1, plasminogen activator inhibitor type-1; sct-PA, single chain t-PA; t-PA, tissue-
plasminogen activator; tct-PA, two-chain t-PA; u-PA, urokinase plasminogen activator.
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(Yepes et al., 2003; Su et al., 2008; Fredriksson et al., 2015;
Lewandowski et al., 2016). The molecular mechanisms for
these physiologic processes include both proteolytic and non-
enzymatic t-PA properties.
Similar to other serine proteases, t-PA is synthesized and
secreted as a zymogen-like molecule, sct-PA. However, in contrast
to other serine protease zymogens, sct-PA exhibits appreciable
proteolytic activity, by some measures demonstrating 25% of the
activity of the fully mature protease, two chain t-PA (tct-PA)
(Boose et al., 1989; Tachias and Madison, 1997). The primary
substrates of t-PA in the CNS are plasminogen and PDGF-CC (Su
et al., 2008; Fredriksson et al., 2015). Studies have also suggested
that the GluN1 subunit of the NMDA receptor can be cleaved by
t-PA. However, the direct cleavage of the NMDA receptor by t-PA
is controversial (Matys and Strickland, 2003; Vivien et al., 2003;
Samson et al., 2008; Yuan et al., 2009). It has also been proposed
that NMDA receptor mediated excitotoxicity is triggered by sct-
PA, and not tct-PA (Parcq et al., 2012; Bertrand et al., 2015),
identifying a potential proteolytic regulatory mechanism based
on the state of the t-PA molecule.
The control of t-PA enzymatic activity is important for
regulation of tPA protease-dependent processes. There are two
primary inhibitors of t-PA in the CNS, PAI-1 (Colucci et al., 1986)
and NSP (Osterwalder et al., 1996; Hastings et al., 1997; Krueger
et al., 1997; Osterwalder et al., 1998; Fredriksson et al., 2015).
Although the amount of PAI-1 in the CNS is small (Yamamoto
et al., 1994; Fredriksson et al., 2015), the molecular chemistry by
which it inhibits t-PA enzymatic activity is well characterized and
is consistent with the current understanding of serine protease
inhibition by a cognate serpin.
Plasminogen activator inhibitor type-1 functions via the
established serpin mechanism, which involves presentation of
a specific peptide bond within the serpin reactive center loop
as a pseudosubstrate for the protease. The protease initiates
cleavage as it would with a substrate, forming an acyl-enzyme
intermediate with the P1 residue of the serpin (Lawrence et al.,
1995; Olson et al., 1995; Wilczynska et al., 1995). However,
before the acyl-enzyme can undergo deacylation to complete
cleavage of the scissile bond, the serpin undergoes structural re-
arrangement, translocating the protease, still covalently linked
to the P1 residue, 70 Å to the opposite pole of the serpin
(Stratikos and Gettins, 1997; Stratikos and Gettins, 1999;
Huntington et al., 2000; Dementiev et al., 2006). Within the
acyl-enzyme complex, the structure of the protease active site
geometry is distorted such that catalytic deacylation can no
longer take occur (Huntington et al., 2000; Dementiev et al.,
2006). The rearranged acyl-enzyme complex exhibits novel
molecular determinants that subsequently mediate specific cell-
surface receptor mediated internalization and degradation of
the protease-serpin complex (Horn et al., 1998; Stefansson
et al., 1998). Hence, protease inhibition by a serpin results
in clearance and degradation of both molecules, constituting
effectively irreversible inhibition.
Our earlier studies noted a potential mechanistic difference
between NSP and PAI-1 inhibition of tPA (Barker-Carlson
et al., 2002). In vitro biochemical studies demonstrated only
transient inhibition of t-PA by NSP due to increased efficiency
of catalytic NSP-t-PA deacylation compared to PAI-1-t-PA
acyl-enzyme complexes (Barker-Carlson et al., 2002). The
shorter period of stable t-PA inhibition by NSP appears to
be biologically meaningful however, as NSP interaction with
t-PA in vivo has been identified as a significant negative-
regulator of t-PA mediated effects on ischemic stroke (Yepes
et al., 2000), seizure propagation (Yepes et al., 2002) and
seizure induced blood brain barrier dysregulation (Fredriksson
et al., 2015). Interestingly, in both the above noted pathologic
states, ischemic stroke and seizure, the pH of the cerebral
spinal fluid decreases to levels that affect the function of
human serine proteases (Siesjo, 1985; von Hanwehr et al.,
1986).
To determine whether the observed differences in NSP
inhibition of t-PA between the in vitro and in vivo systems
might reflect an effect of pH (regulated at 7.2–7.4 in vitro,
and decreased to <6.8 in vivo) we investigated whether the
pH in which NSP-tPA interactions were studied might be a
differentiating factor in these assay systems. The data presented in
this paper demonstrate that although NSP mediated inhibition of
t-PA is less stable than PAI-1 inhibition of t-PA at physiologically
neutral pH, NSP mediated inhibition is modulated by biologically
relevant changes in pH, which result in changes in the rate
of catalytic deacylation of NSP-t-PA complexes. Moreover, pH
differences also allow NSP to differentiate between sct-PA and tct-
PA. This leads us to hypothesize that variations in pH may play
a heretofore unrecognized regulatory role in CNS processes that
involve t-PA.
MATERIALS AND METHODS
Proteins and Reagents
Tissue-t-PA was purchased from Calbiochem (Leola, CA, USA)
and Biopool (Sweden) (>95%, and >99% sct-PA, respectively,
as assessed by SDS-PAGE under reducing conditions followed
by silver staining); tct-PA was generated by treatment of sct-
PA with plasmin-linked sepharose for a time determined to
yield complete conversion of sct-PA to tct-PA as assessed by
SDS-PAGE as above (Schwartz and Espana, 1999). Plasmin,
spectrozyme t-PA, and traysolol were purchased from American
Diagnostica (Greenwich, CT, USA), and two-chain urokinase
(tcu-PA) was obtained from Dr. Gene Murano (Monsanto, St.
Louis, USA). Cell culture grade bovine serum albumin (BSA)
was purchased from Sigma (St. Louis, MO, USA). Recombinant
human PAI-1 (14-1b stabilized mutant) was produced in a
bacterial expression system as previously described (Berkenpas
et al., 1995). Polyclonal rabbit antibody against PAI-1 was
a generous gift of Dr. Peter Andreasen (Aarhus University,
Denmark) (Zeheb et al., 1987). Polyclonal antibody against
NSP was generated in rabbits (Hastings et al., 1997) and HRP-
conjugated goat antibody against rabbit IgG was purchased
from Pierce (Rockford, IL, USA) and Jackson ImmunoResearch
Laboratories (West Grove, PA, USA). Human NSP cDNA was
obtained from Human Genome Sciences (Rockville, MD, USA)
and NSP was expressed in a bacculovirus system (Hastings et al.,
1997).
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Electrophoresis and Western Blot
Analysis
Both the mini-protean three apparatus used for electrophoresis
and protein transfer, as well as electrophoresis reagents were from
BioRad (Hercules, CA, USA). Polyacrylamide gels were cast with
3% stacking and 10% separating gels and Western blotting for
NSP or PAI-1 was carried out as previously described (Barker-
Carlson et al., 2002; Li et al., 2008). Analysis of immunoblots
using known amounts of NSP that was intact, cleaved, or in
complex with sct-PA demonstrated no detectable difference in
epitope detection among the states of NSP (Barker-Carlson
et al., 2002). As noted in our previous paper (Barker-Carlson
et al., 2002) these reagents were validating as demonstrating no
detectable difference in epitope detection among the states of
NSP. This information is included in the “Methods” section.
A standard curve for NSP-sc-tPA complex detection using this
methodology is also included in Supplemental Figures S1A,B.
Kodak 1D Software was used to image all films, and Prism 3.0
or 4.0 software were used for data analysis as indicated.
Assessment of Serpin-PA Complex
Stability as a Function of pH
Seventy nanometer NSP, or 140 nM PAI-1 was incubated at 37◦C
for 5 and 15 min, respectively, with equimolar amounts of the
indicated forms of t-PA, or tcu-PA in 0.1 M NaCl, 0.001 M
sodium phosphate, pH 7.2, and 100 µg/mL BSA. Reactions with
NSP included 0.1% Triton X-100, and those with PAI-1 included
1,000 U/mL trasylol. Preliminary experiments demonstrated
that Triton X-100 had no influence on the function of NSP.
Reactions were then diluted fivefold into a series of 0.1 M sodium
phosphate buffers at the indicated pH values, from 6.0 to 8.0,
and incubated for 30 min (NSP) or 90 min (PAI-1) at 37◦C.
Reactions were quenched by addition of SDS-sample buffer,
boiled and subjected to SDS-PAGE under reducing conditions,
followed by Western blot analysis for NSP or PAI-1. The resulting
immunoblot images were analyzed to quantify remaining acyl-
enzyme serpin-protease complexes as a fraction of the complexes
at time zero.
Effect of pH on Serpin Inhibition of t-PA
Activity
One hundred and thirty-seven nanometer sct-PA or tct-PA was
pre-incubated with 302 nM NSP or 200 nM PAI-1 for 5 (sct-
PA) or 2 min (tct-PA), at 37◦C in 0.15 M NaCl, 0.001 M
Tris, pH 7.2 with 100 µg/mL BSA. Reactions were then diluted
fivefold into buffers containing 0.05 M NaCl, 0.1 M Tris,
100 µg/mL BSA at the pH’s indicated, and incubated a further
50 min (sct-PA) or (tct-PA), or 30 min at 37◦C. Reactions with
NSP contained 0.1% Triton X-100. Residual t-PA activity was
determined by adding spectrozyme t-PA at a final concentration
of 1.5 mM using the kinetic analysis module in a Beckman DU-
640 spectrophotometer. Inhibition of t-PA enzymatic activity was
calculated as shown in Equation 1.
Equation 1:
100− 100(t-PA− serpinpHx/t-PApHx) = %t-PA inhibition
Where t-PA-serpinpHx represents the rate of chromogenic
substrate cleavage in reactions containing t-PA and the indicated
serpin at a specific pH between 6.0 and 8.0, and t-PApHx
represents the rate of chromogenic substrate cleavage by t-PA at
the same pH in the absence of serpin.
Neuroserpin-t-PA (either form of t-PA) acyl-enzyme
complexes demonstrated no catalytic deacylation at pH 6.0, thus
inhibition of t-PA activity at pH 6.0 was designated 100%, and
inhibition at other pH’s was expressed relative to that at pH 6.0,
as shown in Equation 2.
Equation 2:
% t-PAinhibitionpHx/% t-PAinhibitionpH6.0 =
t-PA inhibition relative to that at pH 6.0
Where % t-PA inhibition pHx represents the percent
inhibition of t-PA at the indicated pH, and % t-PA inhibition
pH6.0 is the percent inhibition at pH 6.0, both determined as in
Equation 1. The pH profile for the relative inhibition of t-PA by
NSP was generated and fit to a sigmoidal curve with variable slope
non-linear regression using Prism 4.0 software.
Effect of pH on the Rate of NSP-t-PA
Acyl-Enzyme Complex Deacylation
Formation of acyl-enzyme complexes between each form of
t-PA and NSP progresses more rapidly than does deacylation
(Barker-Carlson et al., 2002). Preliminary experiments defined
conditions wherein NSP-t-PA acyl-enzyme complex formation
had gone to completion, and therefore the decrement in NSP
within those complexes over time could be quantified. Equimolar
concentrations (70 nM) of NSP and sct-PA, or tct-PA were
incubated for 10 or 2 min, respectively, at 37◦C in 0.1 M
NaCl, 0.001 M sodium phosphate, pH 7.2, with 100 µg/mL BSA
and 0.1% Triton X-100. Reactions were then diluted fivefold
(final concentration of t-PA and NSP, 14 mM) into 0.1 M
sodium phosphate buffer, at the indicated pH between 6.0 and
7.6, containing 100 µg/mL BSA and 0.1% Triton X-100, and
incubated at 37◦C. At sequential times, aliquots were removed
and quenched by addition of SDS-sample buffer, boiled, and
analyzed by SDS-PAGE under reducing conditions, followed
by Western blot analysis of NSP antigen. The deacylation rate
constant at each pH was determined by fitting the data for the
decay of NSP-t-PA acyl-enzyme complexes, which was linear
with respect to time at each pH tested, to the equation for
unimolecular decay (Equation 3).
Equation 3:
ln[NSP-t-PA]t = ln[NSP-t-PA]o − k3t
Where [NSP-t-PA]t is the concentration of NSP-t-PA acyl-
enzyme complexes at time t, [NSP-t-PA]o is the initial
concentration of complexes, and k3 is the deacylation rate
constant (Schechter et al., 1997; Plotnick et al., 2002a,b; Schechter
and Plotnick, 2004).
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RESULTS
Previous work from our labs revealed that the interaction
between t-PA and NSP did not form the prototypically stable
serpin-protease acyl-enzyme complexes as seen with t-PA and its
other cognate serpin, PAI-1. Rather, formation of acyl-enzyme
complexes between t-PA and NSP occurred readily, but was
followed by rapid deacylation yielding cleaved serpin and active
enzyme (Barker-Carlson et al., 2002). In contrast to these unstable
in vitro NSP-t-PA complexes, administration of NSP to animals
undergoing experimental stroke or seizure yielded evidence of
t-PA inhibition (Osterwalder et al., 1998; Yepes et al., 2000, 2002).
Unlike in vitro biochemical experiments which are generally
performed at pH 7.2–7.4, the CNS is relatively poorly buffered
and its pH drops to as low as 6.0 during pathologies wherein
t-PA plays a role (Meldrum and Brierley, 1973; Meldrum and
Horton, 1973; Aminoff and Simon, 1980; Siesjo, 1985, 1986,
1992; von Hanwehr et al., 1986; Bereczki and Csiba, 1993; Meric
et al., 1994). We hypothesized that the rapid drop in CNS pH
documented to occur following the onset of stroke or seizure
might influence the stability of NSP-t-PA acyl-enzyme complexes,
and the accompanying inhibition of t-PA enzymatic activity.
To test this hypothesis, NSP was allowed to complex
with either sct-PA or tct-PA at pH 7.2, aliquots were then
brought to different pH’s across the range of 6.0–8.0 and
incubated a further 30 min at 37oC. The reactions were
then analyzed by SDS-PAGE and Western blotting for NSP
antigen, and the amount of NSP that remained in complex
was compared to the amount initially present in acyl-enzyme
complex. Figure 1 demonstrates several findings. First, the effect
FIGURE 1 | Stability of t-PA-NSP acyl-enzyme complexes is pH dependent. (A) Following initial formation of NSP t-PA complexes with NSP at pH 7.2,
reactions were diluted into buffers between 6.0 and 8.0 and incubated at 37◦C for an additional 30 min as detailed in Methods, then analyzed by SDS-PAGE and
Western blotting for NSP. The far left lane illustrates the quantity of NSP-t-PA complexes present at the beginning of the 30-min incubation (maximal complex). The
far right lane contains NSP that was not reacted with t-PA. The remaining lanes show the reaction products at the end of the 30-min incubation at each noted pH.
The identities of the individual bands are indicated on the left side of the gel. For ease of comparison, reactions with sct-PA and tct-PA were run in the same wells,
since the NSP-t-PA acyl-enzyme complexes involving each form of t-PA are easily resolved. Identical results were obtained when reactions between NSP and each
form of NSP were analyzed separately. (B) The ratio of t-PA-NSP complex remaining at the end of the 30-min incubation at the indicated pH, to the amount of
complex present immediately before dilution into various pH buffers was graphed as a function of the pH into which the reactions were diluted. Triangles: NSP-tct-PA
complexes; Squares: NSP-sct-PA complexes. Data are presented as points that represent the individual values, from 3 independent experiments, and lines that
represent the means of those values.
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of pH on acyl-enzyme stability is clearly different for NSP in
complex with sct-PA compared to NSP in complex with tct-
PA. Second, the difference in acyl-enzyme stability between
NSP in complex with the two forms of t-PA is greatest at
physiologic pH, 7.4. Third, although acyl-enzyme complexes
between NSP and tct-PA are unstable at pH 7.4 suggesting
tct-PA is free to exert proteolytic activity at physiologic pH,
slight acidic shifts result in significant stabilization of these
complexes.
The loss of acyl-enzyme complexes does indeed signify
catalytic deacylation, as the appearance of cleaved NSP
accounts for the reduction in acyl-enzyme-complex with t-PA
(Figure 1A), and the pH range in which this occurs is not
compatible with hydroxide mediated deacylation (Calugaru
et al., 2001). These findings are consistent with the mechanism
for catalytic deacylation of an acyl-enzyme intermediate of a
serine proteinase, which requires that the active site histidine
within the catalytic triad accept a proton (Plotnick et al.,
2002a). At lower pH values, the histidine is likely already
protonated, and thus catalytic deacylation cannot proceed.
These data are also consistent with previous observations that
at pH 7.2, deacylation readily occurs (Barker-Carlson et al.,
2002).
These effects do not seem to be general characteristics of
t-PA-serpin interactions, as PAI-1-t-PA acyl-enzyme complexes
are stable across the pH range in which NSP-t-PA complexes
undergo catalytic deacylation, and no differential stability
between PAI-1-sct-PA complexes and PAI-1-tct-PA complexes
was evident (Figures 2A,B). In addition, this pattern of acyl-
enzyme instability does not characterize NSP interactions with
other proteases closely related to t-PA. Under no circumstances
tested were acyl-enzyme complexes between plasmin and
NSP detected, but instead NSP acted as a pure plasmin
substrate across the pH range tested (data not shown). Two-
chain u-PA cleaved NSP with no detectable acyl-enzyme
intermediate at physiologic pH, essentially treating the serpin
as a substrate. However, rapid adjustment of conditions
to very acidic pH allowed detection of stable tcu-PA-NSP
acyl-enzyme complexes (Figure 2C). This is consistent with
the pattern observed for non-cognate protease-serpin pairs
FIGURE 2 | (A,B) pH dependent stability of acyl-enzyme complexes is specific for NSP-t-PA complexes. PAI-1-t-PA complex stability was assayed in a manner
analogous to NSP-t-PA complex stability, as described in Methods. The ratio of PAI-1-t-PA complex remaining at the end of the 90-min incubation to the amount of
complex present immediately before dilution into various pH buffers, was graphed as a function of the pH into which the reactions were diluted. Triangles:
PAI-1-tct-PA complexes; Squares: PAI-1-sct-PA complexes. Data are presented as points that represent the individual values, from 3 independent experiments Note
that incubation of PAI-1-t-PA complexes at various pH’s was for 90 min, compared to 30 min for NSP-t-PA complexes, further illustrating the difference in stability
between the acyl-enzyme complexes. Panel (B) is a representative western blot from which the data were derived and quantified for (A). (C) tcu-PA and NSP were
incubated in buffer pH 7.2 for 1 min at 37◦C, diluted fivefold into buffers at the indicated pH, and incubated at 37◦C for 3 h. Samples were then analyzed by
SDS-PAGE and western blotting for NSP as described in Methods. The ratio of the concentration of the tcu-PA-NSP complexes remaining after the 3-h incubation at
each pH to the concentration of complex present immediately before dilution into various pH buffers was graphed against the pH into which the reactions were
diluted.
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FIGURE 3 | Inhibition of t-PA enzymatic activity by NSP, but not PAI-1, is dependent on pH. Sct-PA or tct-PA were pre-incubated with either (A) NSP, or
(B) PAI-1 as detailed in Methods. Reactions were then diluted into buffers with the indicated pH’s as in Methods, and the residual t-PA activity determined by
quantifying cleavage of a chromogenic substrate. The per cent t-PA inhibition at a given pH was compared to the maximum inhibition (observed at pH 6.0) to yield
the relative inhibition of each form of t-PA, which is graphed as a function of pH. Triangles: Serpin-sct-PA complexes; Squares: Serpin-tct-PA complexes. Data
represent the mean and SEM from 3 independent experiments.
(Schechter et al., 1997; Plotnick et al., 2002a,b; Schechter
and Plotnick, 2004). Although single chain u-PA forms acyl-
enzyme complexes with PAI-1 (Manchanda and Schwartz,
1995), no complexes between single chain u-PA and NSP
were detected (data not shown). Hence, the regulation of NSP
inhibition of t-PA over the narrow pH range known to occur
in physiologic and pathologic processes in the mammalian
CNS seems selective for this protease-serpin pair. This is in
marked contrast to t-PA and u-PA reacting with the serpin
PAI-1, and with the substrate plasminogen (Colucci et al.,
1986), and is consistent with the findings of Fredriksson
et. al., which suggests that NSP regulates a t-PA mediated
process (Fredriksson et al., 2015). The intriguing possibility
raised by the present data is that there may be selectivity for
regulating the different forms of t-PA under certain biological
conditions.
Stability of an acyl-enzyme complex suggests the active
site architecture of the protease remains distorted within the
complex, preventing catalytic deacylation (Lawrence et al., 1990;
Huntington et al., 2000; Dementiev et al., 2006). Therefore,
the pH dependent change in NSP-t-PA acyl-enzyme complex
stability should be paralleled by a pH dependent change in
t-PA inhibition. To test this, NSP and both forms of t-PA
(sct-PA or tct-PA) were incubated at pH 7.2 to allow acyl-
enzyme complexes to form. The complexes were then diluted
into buffers with pH’s between 6.0 and 8.0, incubated further,
and then added to a t-PA sensitive chromogenic substrate to
determine residual t-PA catalytic activity, and thus the degree
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of t-PA inhibition. As seen in Figure 3, t-PA inhibition as
a function of pH closely paralleled the persistence of NSP-
t-PA acyl-enzyme complexes as a function of pH (compare
Figures 1B and 3A). In addition, the surprising difference in
pH effect on acyl-enzyme complex stability between sct-PA and
tct-PA was also seen in pH dependent inhibition of the two
forms of t-PA (Figure 3A). As was seen with acyl-enzyme
complex persistence, this pattern of inhibition was unique to
the interaction between t-PA and NSP, as PAI-1 showed no
difference in t-PA inhibitory efficiency across the pH range
tested, nor did PAI-1 differentiate between the two forms of
the enzyme (Figure 3B). These data also suggest that the
pH dependent difference in acyl-enzyme complex persistence
was not a function of an SDS-PAGE based assay system, as
the experiments determining inhibition of enzymatic activity
contained no denaturants.
The above data suggest that NSP may have the capacity
to differentially inhibit sct-PA and tct-PA via distinct rates
of deacylation of the acyl-enzyme complexes once they are
formed. To test this hypothesis, NSP-sct-PA and NSP-tct-PA acyl-
enzyme complexes were pre-formed, transferred to the indicated
pH, and rates of acyl-enzyme complex deacylation determined.
To ensure the data were not confounded by the formation
of new NSP-t-PA acyl-enzyme complexes, measurement of
NSP-t-PA complex decay was only performed at times after
all NSP had been incorporated into acyl-enzyme complexes,
as assessed by SDS-PAGE and western blotting for NSP.
Hence, the reduction in NSP-t-PA complex intensity was an
accurate measure of deacylation. As seen in Figure 4, the
plots of the deacylation rate constants as a function of pH
differed between NSP in complex with sct-PA, and tct-PA.
In addition, the rate constants were consistent with the pH
dependent acyl-enzyme persistence and enzyme inhibition with
each form of t-PA (Figures 1 and 3). NSP-tct-PA deacylation
FIGURE 4 | Differential effects of pH on the deacylation rates of
NSP-sct-PA and NSP-tct-PA acyl-enzyme complexes. Acyl-enzyme
complex formation between sct-PA or tct-PA and NSP was allowed to
progress to completion at pH 7.2, as determined in preliminary experiments.
Individual reactions were then transferred to the indicated pH and the decay of
acyl-enzyme complexes followed over time by subjecting aliquots to
SDS-PAGE and western blotting for NSP antigen as detailed in Methods. The
deacylation rate constant (k3) was determined for each pH as described in
Methods. Triangles, NSP-sct-PA complexes; Squares, NSP-tct-PA
complexes. Data are representative of two independent sets of experiments.
rates remained low below pH 7.0, the range where acyl-
enzyme complexes persisted and tct-PA enzymatic activity was
inhibited. As the pH increased above 7.0, the deacylation rate
increased (Figure 4), with parallel decreases in acyl-enzyme
complex persistence (Figure 1B) and enzymatic inhibition
(Figure 3A). For NSP in complex with sct-PA, the increase
in deacylation rate occurred at a significantly higher pH, 7.4,
again with corresponding changes in acyl-enzyme complex
persistence and enzyme inhibition (Figures 1B and 3A,
respectively).
DISCUSSION
Given the relatively steep slope of the pH effect on NSP
inhibition of t-PA, and the similar slopes of pH dependent
stability for acyl-enzyme complexes containing either form of
t-PA (Figure 1B), it seems that this pH effect is due to a
limited number of residues. The pH range across which NSP-t-PA
catalytic deacylation is regulated is consistent with titration of the
catalytic triad histidine (HIS 57, chymotrypsin numbering), and
suggests significantly different molecular environments for HIS
57 of sct-PA versus tct-PA in complex with NSP, with a different
H+ ion concentration required to allow initiation of catalytic
deacylation. However, once that threshold has been crossed, the
similar titration curves for deacylation of NSP in complex with
sct-PA or tct-PA suggests a similar process for each form of
t-PA.
It is also possible that the distinct pH profiles of deacylation
signify differences in a non-active site residue on either
molecule important for maintaining t-PA in the deformed
conformation (i.e., at a contact point between protease and
serpin). For instance, it is possible that as a residue at
the interface between t-PA and NSP is deprotonated, the
ability of NSP to maintain misalignment of t-PA’s active site
architecture is lost, resulting in recovery of the capacity for
catalytic deacylation of the acyl-enzyme complex. If so, the
pH sensitivity of this residue in NSP-sct-PA complexes must
differ from that in NSP-tct-PA complexes. Such a scenario
would also yield a difference primarily in the threshold at
which deacylation is initiated, with subsequent events being
similar between forms of t-PA. It will be important to test
these and other hypotheses of the molecular mechanism for
the differential pH effects on NSP-t-PA deacylation in future
experiments.
This model is consistent with the findings of Calugaru
et al. (2001), who observed that in certain non-cognate serpin-
protease pairs, Ca++ served as an allosteric ligand which
restored partial proteolytic capability to the serpin-complexed
protease active site, allowing for catalytic deacylation of the
serpin-protease intermediate. In the case of NSP-t-PA complexes,
there does not appear to be a requirement for an allosteric
ligand to bring about a pH responsive conformation; such a
conformation appears to have evolved specifically in NSP-t-PA
complexes.
An intriguing correlation may be made with recent findings
by Lee et al. (2015), who showed that NSP-t-PA complex
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stability is dependent on evolutionarily conserved residues in
NSP, and their findings will inform design of future NSP-
mutants to identify the amino acid residues that are ultimately
responsible for the pH dependency of NSP-t-PA complex
deacylation.
The findings in this report are also consistent with a
population of NSP-complexed t-PA molecules that retain some
degree of catalytic function in equilibrium with NSP- complexed
t-PA molecules exhibiting little or no catalytic function, as
hypothesized for unstable serpin-enzyme pairs (Calugaru et al.,
2001; Plotnick et al., 2002b). As the somewhat functional
t-PA molecules complete the catalytic cleavage of NSP, an
essentially irreversible event, the equilibrium model suggests
that some molecules in the non-functional conformation then
shift to the somewhat functional state, and further catalytic
deacylation of complexed NSP occurs. This is depicted in Scheme
1.
Scheme 1:
t-PAD −NSP t-PAF −NSP→ t-PA + NSPcleaved
where t-PAD is deformed and catalytically inactive t-PA in
complex with NSP, t-PAF is t-PA that has retained some catalytic
function in complex with NSP, and NSPcleaved is NSP that has
had the cleavage of P1–P1′ completed. Therefore, the catalytic
activity of the t-PAF form of the protease might be pH sensitive
(presumably due to titration of HIS 57), or the stabilization of
the t-PAD-NSP complex might be pH dependent (presumably via
optimization of intermolecular contacts).
It is interesting that despite the metabolic fragility of the CNS,
the CSF has relatively poor buffering capacity. This suggests
that allowing changes in CNS pH may have been preserved
through evolution, a concept that is consistent with pH having an
important regulatory role in the in this anatomic compartment.
The data in this paper suggest that specific regulation of t-PA
activity by NSP may be an example of a process regulated
by shifts in CNS pH. For instance, neuronal depolarization
is accompanied by a flux of hydrogen ions at the synapse,
and similarly, secretion of NSP-containing dense core secretory
vesicles, which have a pH of 5.0–6.0, would also be expected to
transiently lower the local synaptic pH (Loh et al., 1984; Chuang
et al., 1999; Parmar et al., 2002; Ishigami et al., 2007). Additional
mechanisms of synaptic pH modulation include the Ca+2/H+-
ATPase and carbonic anhydrases that are all functional within
the microdomain of the synapse (Sinning and Hubner, 2013).
A shift in pH within a single synapse could be sufficient to
modulate NSP inhibitory stability, resultant t-PA activity, and
t-PA-dependent neuronal function for that specific synapse (Qian
et al., 1993; Seeds et al., 1995; Frey et al., 1996; Calabresi et al.,
2000; Zhuo et al., 2000). These same pH alterations can also be
hypothesized to modify NMDA receptor activity (Tang et al.,
1990; Traynelis and Cull-Candy, 1990; Sinning and Hubner,
2013), with relatively little effect on AMPA- and kainite receptor
function (Lei et al., 2001). Although beyond the scope of this
manuscript, it is tempting to speculate that the inhibition of
NMDA receptor activity noted with decreased extracellular pH
may in part be related to persistence of NSP-t-PA acyl-enzyme
complexes, thus altering t-PA interaction with the NR2B subunit
of the NMDA receptor (Norris and Strickland, 2007; Parcq et al.,
2012).
It is also intriguing to speculate that pH dependent regulation
of t-PA proteolytic activity may be operative in pathologic
instances such as seizures, where depolarization goes unchecked.
The spread of seizures in mice is t-PA dependent (Yepes et al.,
2002), and in a murine model of neonatal febrile seizures,
hyperventilation driven alkalinization of the CSF was shown to
be the trigger for seizures (Schuchmann et al., 2006). This is
consistent with the use of hyperventilation to induce seizures
during video EEG monitoring to determine seizure focus in
the CNS (Guaranha et al., 2005). Perhaps hyperventilation-
induced CNS alkalinization results in loss of NSP inhibitory
activity, releasing unopposed t-PA activity, thus facilitating
seizure spread.
NSP polymerization has also been shown to be dependent on
pH (Belorgey et al., 2010, 2011), and NSP is more resistant to
polymerization at low pH than is PAI-1 (Ishigami et al., 2007;
Takehara et al., 2009; Belorgey et al., 2010). Because available
NSP or PAI-1 is a function of the balance between polymerized
and free serpin, with only free serpin being able to complex
with protease, it is possible that the pH effect described in
the present report reflects differences in NSP polymerization,
and thus differences in the serpin’s availability to inhibit t-PA.
However, deacylation was determined starting with NSP that was
already in complex with each form of t-PA (Figure 4), something
that requires non-polymerized NSP. Hence, the regulatory step
described here appears to be separate from the pH effect on NSP
polymerization.
It is also worth considering whether differential pH-dependent
regulation of sct-PA and tct-PA reflects different functions for
each form of the protease in the CNS. This differentiation may
reflect one reason t-PA evolved uniquely as a protease with
such a remarkably active zymogen, and is consistent with the
distinct role of sct-PA in activating NMDA receptor-dependent
neurotoxicity (Parcq et al., 2012; Bertrand et al., 2015) Moreover,
Parmar et al.’s finding that tct-PA forms acyl-enzyme complexes
with NSP at lower pH than does sct-PA (Parmar et al., 2002) is
consistent with different molecular environments in the active
sites of the two forms of t-PA during acyl-enzyme formation.
Those data, combined with the findings in this paper regarding
acyl-enzyme stability, strengthen the hypothesis that changes
in H+ ion concentrations are important in regulating the
interaction of NSP and t-PA.
Importantly, the properties of NSP that make it uniquely
suited as a differential regulator for two forms of t-PA in the
pH-sensitive environment of the CNS support the conclusion
of Fredriksson et al. (2015) that t-PA is a physiologic target of
NSP in the CNS. This is further supported by recent findings
that there is very little PAI-1 in neuronal tissue of the normal
brain, further supporting the important regulatory function of
NSP for t-PA inhibition in the extravascular compartment of the
CNS (Yamamoto et al., 1994; Fredriksson et al., 2015).
Further studies will be required to define the molecular
mechanisms and physiologic import of this novel form of
protease regulation.
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